中药抗病毒制剂治疗年轻女性宫颈高危型HPV感染的临床观察
[Abstract]:Objective: to study the clinical study on the treatment of high risk human papillomavirus (high-risk Human Papilloma Virus, hrHPV) infection of cervix of young women with dampness and heat by contrasting pidomod oral liquid (commercial name: Fructus decoction) with antiviral preparation of traditional Chinese medicine. To evaluate the efficacy and safety of traditional Chinese medicine antiviral preparations. Methods: a total of 60 patients with hrHPV infection, aged 25-35 years, who were admitted to the department of gynecology of Changzhou traditional Chinese Medicine Hospital from June 2015 to December 2015, were randomly divided into two groups. The control group (Flo Yin group) and the treatment group (traditional Chinese medicine antiviral preparation group), 30 cases in each group, were treated according to the research plan. The clinical efficacy of traditional Chinese medicine antiviral preparation was evaluated by comparison before and after treatment and between the two groups. The safety of traditional Chinese medicine antiviral preparations was evaluated by observing the clinical biochemical indexes of the treatment group. Results: 1. Comparison of TCM clinical symptom scores: (1) comparison of TCM symptom scores before and after treatment: after treatment, the clinical symptoms of young female patients with hrHPV infection with rich neck were obviously improved in the treatment group. In the control group, there was no or only slight improvement in the subband condition and systemic symptoms after treatment. (2) comparison of the total score of TCM clinical symptoms: the total score of TCM clinical symptoms in the treatment group was significantly different before and after treatment. Statistical significance (p0. 00. P0.01), the control group had no significant significance in the clinical symptom score before and after treatment, and the comparison between the two groups, The difference was statistically significant (p0. 05). The comparison of viral load and negative rate of 2.hrHPV: (1) the viral load of treatment group and control group were significantly different before and after treatment. The difference of viral load between the two groups before and after treatment was statistically significant (p0. 01% p0. 05), and the decrease of hrHPV viral load in the treatment group was significantly better than that in the control group. There was significant difference between the two groups (p0. 05). (2). In the control group, the rate of turning negative after 3 months and 6 months was 20 and 33. 3 respectively. In the treatment group, the rate of turning negative after 3 months and 6 months was 36. 7% and 63. 3% respectively. After 3 months and 6 months of treatment, there were significant differences in the rate of negative conversion between the two groups (p 0.05). Comparison of the total effective rate before and after treatment: the cure rate of the control group was 10, the total effective rate was 63.3, the cure rate of the treatment group was 26.7and the total effective rate was 86.7. The total effective rate of the two groups was significantly higher than that of the control group (p0. 00p 0. 01). 4. Safety observation: the liver and kidney function, blood and urine routine, coagulation function and blood biochemistry were not abnormal in the treatment group after 3 months and 6 months, and there were no obvious adverse reactions associated with taking drugs during the treatment period. Conclusion: both antiviral preparations and Fructus decoction can significantly shorten the time limit of self-healing of cervical hrHPV infection in young women, eliminate hrHPV virus, reduce viral load and improve the clinical symptoms of the patients. Early intervention of Chinese and western medicine has significant clinical significance, and the effect of traditional Chinese medicine is obviously better than that of western medicine. Traditional Chinese medicine is economical and safe without toxic side effects.
【学位授予单位】:南京中医药大学
【学位级别】:硕士
【学位授予年份】:2016
【分类号】:R271.9
【相似文献】
相关期刊论文 前10条
1 赵进生;吴鸿银;;抗病毒制剂——干扰素(Интереферон)[J];南药译丛;1961年01期
2 张雅德;;治疗流感的新抗病毒制剂是否能满足临床需要[J];国外医学情报;1998年03期
3 孙敬方;刘兴福;;新型禽用抗病毒制剂的研制与应用[J];实验动物与比较医学;2006年03期
4 史久华;;即将问世的基因工程制品[J];国外医学.生物制品分册;1983年03期
5 黄大有;病毒生物学及抗病毒制剂的某些新进展[J];北京医学院学报;1983年01期
6 孙永涛,白雪帆,SylviaLee-huang;新一代抗病毒制剂——MAP30[J];肝脏;2001年S1期
7 陈春荣;防止危险药品对护士造成危害[J];国外医学.护理学分册;2002年09期
8 王勇翔;;干扰正常衣壳蛋白组装的小分子物质可发展成抗病毒制剂[J];国外医学(微生物学分册);2003年02期
9 王临旭;孙永涛;杨为松;;新一代抗HIV植物蛋白-MAP30[J];传染病信息;2002年01期
10 褚盘棣;;日本新开发的生物制品和抗病毒制剂[J];药学进展;1990年01期
相关会议论文 前4条
1 张代宝;吴志明;赵明军;王淑娟;谢彩华;张林海;闫若潜;;鸡基因工程复合抗病毒制剂冻干保护剂的筛选[A];中国畜牧兽医学会动物传染病学分会第十二次人兽共患病学术研讨会暨第六届第十四次教学专业委员会论文集[C];2012年
2 闫若潜;谢彩华;张志凌;刘梅芬;盛敏;吴志明;;鸡基因工程重组复合抗病毒制剂研究[A];中国畜牧兽医学会2008年学术年会暨第六届全国畜牧兽医青年科技工作者学术研讨会论文集[C];2008年
3 张国刚;王欢;徐绥绪;;抗病毒制剂中黄芩苷在大鼠体内的药代动力学研究[A];药用植物研究与中药现代化——第四届全国药用植物学与植物药学术研讨会论文集[C];2004年
4 杨劲;李杰;吴南屏;吕杭军;张永乐;徐岱;;SMAP与竞争探针联合使用检测点突变[A];2012年浙江省医学会肝病、感染病学学术年会暨浙江省感染科医师学术年会论文集[C];2012年
相关博士学位论文 前1条
1 王临旭;植物蛋白MAP30的制备及其体外抗病毒活性的实验研究[D];中国人民解放军第四军医大学;2003年
相关硕士学位论文 前3条
1 郭圆;杀虫剂和抗病毒制剂对蚜虫翅型分化及发育和生殖的影响[D];华中农业大学;2016年
2 王静;中药抗病毒制剂治疗年轻女性宫颈高危型HPV感染的临床观察[D];南京中医药大学;2016年
3 张代宝;鸡基因工程复合抗病毒制剂的冻干、安全性及体外抗病毒活性研究[D];河南科技大学;2012年
,本文编号:2397059
本文链接:https://www.wllwen.com/zhongyixuelunwen/2397059.html